Article Text

Download PDFPDF
The potential role of neoadjuvant chemotherapy in advanced ovarian cancer
  1. M. Baekelandt*
  1. * Department of Gynecological Oncology, The Norwegian Radium Hospital, Oslo, Norway
  1. Address correspondence and reprint requests to: Dr M. Baekelandt, MD, PhD, Department of Gynecological Oncology, The Norwegian Radium Hospital, Montebello, 0310 Oslo, Norway. Email: mark.baekelandt{at}


There is a multitude of evidence from retrospective analyses and meta-analyses showing that the amount of residual tumor after debulking surgery and before chemotherapy is one of the most powerful prognostic determinants in advanced ovarian cancer. This supports the important role of maximum cytoreductive surgery as one of the cornerstones in the treatment of this disease. These same analyses, however, do not suggest that patients whose tumors cannot be debulked optimally derive a significant survival benefit from upfront surgery. For these patients and those who have a poor performance status or other morbidity, making comprehensive upfront surgery contraindicated, different therapeutic approaches have to be explored. One possible way to go is to change the timing of the different therapeutic modalities: upfront chemical cytoreduction, followed by a maximal surgical effort, in turn followed by the remainder of the first-line chemotherapy or neoadjuvant chemotherapy and interval or delayed debulking surgery. The potential role of this approach and the experience with it thus far are discussed.

  • advanced ovarian cancer
  • neoadjuvant chemotherapy
  • surgery

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.